KPRX
HEALTHCAREKiora Pharmaceuticals Inc
Live · NASDAQ · May 9, Close
What's Moving KPRX Today?
No stock-specific AI insight has been generated for KPRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.51
Fundamentals
Trading
KPRX News
20 articles- Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 8, 2026
- Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial UnderwayYahoo Finance·Apr 14, 2026
- Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical PipelineYahoo Finance·Apr 9, 2026
- Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive AdvisorsYahoo Finance·Apr 7, 2026
- Kiora Pharmaceuticals Announces Management Team ChangesYahoo Finance·Apr 2, 2026
- Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical TrialsYahoo Finance·Mar 25, 2026
- Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 19, 2026
- Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory BoardYahoo Finance·Jan 27, 2026
- Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory CompoundsYahoo Finance·Dec 1, 2025
- Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal DiseasesYahoo Finance·Nov 7, 2025
- Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular DisordersYahoo Finance·Oct 30, 2025
- Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025Yahoo Finance·Oct 15, 2025
- Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 4, 2025
- Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal DiseasesYahoo Finance·Aug 8, 2025
- Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceYahoo Finance·Aug 7, 2025
- Vicarious Surgical names Stephen From as next CEOMedtechdive·Aug 1, 2025
- Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular DiseaseYahoo Finance·Jul 22, 2025
- Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should KnowYahoo Finance·Jul 16, 2025
- Top Midday GainersYahoo Finance·Jun 3, 2025
- Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaYahoo Finance·Jun 3, 2025
All 20 articles loaded
Price Data
52-Week Range
$2.51
Fundamentals
Trading
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm dedicated to developing transformative therapies for ocular diseases and neurodegenerative disorders. The company's robust pipeline of innovative drug candidates aims to meet critical unmet medical needs, utilizing its advanced expertise in drug formulation and delivery systems to propel clinical trials toward regulatory approval. Kiora's focus on improving patient outcomes, complemented by strong research capabilities and strategic collaborations, enhances its competitive position within the biopharmaceutical sector, making it an appealing investment opportunity for institutional investors interested in pioneering therapeutics.